Interrogation of the immune microenvironment of T-cell malignancies

ImmuneT-ME is an EU-wide consortium of nine partners dedicated to decoding the immune tumor microenvironment in mature T-cell malignancies to enable biomarker-driven, personalized therapies.

All news

EP PerMed · Award

EP PerMed Networking Support Award for IMPACT-T

IMPACT-T has been awarded funding through the EP PerMed Networking Support Call 2025, enabling the IMPACT-T meeting on 26–27 January 2027 at Design Offices Leipzig, bringing together clinicians, researchers, patient advocates, policymakers and industry partners from across Europe. The meeting focuses on translational barriers to personalised medicine in T-cell leukemias and lymphomas (TCLs), building on JAKSTAT-TARGET, ImmuneT-ME and SURPASS-TNBC, working towards biomarker-driven trial concepts and sustainable networks.

Read more

25–26 Feb 2026 · Cologne

First In-Person Consortium Meeting in Cologne

On 25–26 February 2026, partners of the ImmuneT-ME network met in Cologne for the first in-person consortium meeting. Over two days, participants exchanged updates, discussed project progress, and explored future collaborative initiatives, alongside a guided city tour.

Read more

Publication · HemaSphere

New Publication on JAK Inhibition in HSTL

A study led by Heidi Neubauer investigates JAK inhibition as a targeted strategy in hepatosplenic T-cell lymphoma (HSTL). In collaboration with partners Marco Herling and Tero Aittokallio, the study establishes STAT5B-driven preclinical models and identifies upadacitinib as a promising candidate for STAT5B-mutated cases.

Read more

Nine partners across Europe

Cancer biologists, clinical hematologists, immunologists, computational scientists and pan-European patient organizations, led by their Principal Investigators.